U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	ute for form 1449B/PTO	Compl te if Known		
INFORM	MATION DISCLOSURE	Application Number	10/419,059	
PE COSSTATE	MENT BY APPLICANT	Filing Dat	04/17/2003	
		First Named Inventor	Kenneth F. Buechler	
A TOTAL TE		Group Art Unit	'Unassigned	
(use as many sheets as necessary)		Examiner Name	Unassigned	
Sheet 🐉	of, 8	Attorney Docket Number	071949-7001	

		U.S. Patent [	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
186	A1	5,480,792		Buechler et al.	Jan. 2, 1996	
	A2	5,525,524		Buechler et al.	June 11, 1996	
	A3	5,571,698		Ladner et al.	Nov. 5, 1996	,
	·A4	5,631,171		Sandstrom et al.	May 20, 1997	
	A5	5,679,526		Buechler et al. ·.	Oct. 21, 1997	
	A6	5,719,060		Hulchens et al.	Feb. 17, 1998	
	A7	5,824,799		Buechler et al.	Oct. 20, 1998	
	A8	5,851,776		Valkirs	Dec. 22, 1998	
	A9	5,885,527		Buechler	March 23, 1999	
	A10	5,894,063		Hutchens et al.	Apr. 13, 1999	
	A11	5,922,615		Nowakowski et al.	July 13, 1999	
	A12	5,939,272		Buechler et al.	Aug. 17, 1999	·
	A13	5,947,124		Buechler et al.	Sept. 7, 1999	
	A14	5,955,377		Maul et al.	Sept. 21, 1999	
	A15	5,985,579		Buechler et al.	Nov. 16, 1999	
	A16	6,019,944		Buechler	Feb. 1, 2000	
	A17	6,020,208		Hutchens et al.	Feb. 1, 2000	
·	A18	6,027,942		Hutchens et al.	Feb. 22, 2000	
	A19	6,057,098		Buechler et al.	May 2, 2000	:
	A20	6,107,623		Bateman et al.	Aug. 22, 2000	:
	A21	6,113,855		Buechler	Sept. 5, 2000	
	A22	6,124,137		Hutchens et al.	Sept. 26, 2000	
	A23	6,143,576	· .	Buechler	Nov. 7, 2000	•
	A24	6,204,500		Whitehouse et al.	March 20, 2001	
	A25	6,225,047		Hutchens et al.	May 1, 2001	
LYL	A26	6,268,144		Koster	July 31, 2001	

<u> </u>				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. <sup>1</sup>	Office:	oreign Patent C 3 Number4	locument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	, T6
· LYL	A27	wo	O2/083913		Biosite Diagnostics, Inc.	Oct. 24, 2002		1
146	A28	WO	02/089657		Biosite, Inc.	Nov. 14, 2002		1.
LYL	A29	wo	03/016910		Biosite, Inc.	Feb. 27, 2003		1
								<b></b>

Examiner Signature Date Considered 7/19/06
--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). °For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	r form 1449B/	PTO	OIPE		Complete if Known	
	INFORMATIC	ON DISCLO	SURF		Applicati n Numb r	10/419,059	
	STATEMENT	BY APPLI	CANT	•	kiling Dat	04/17/2003	
			L	MOV 1 2 200	First Named Inv ntor	Kenneth F. Buechler	
			E		Group Art Unit	Unassigned	
	(use as many sl	heets as ne	cesso	(Y)	Examiner Name	Unassigned	·····
Sheet	2	of	8	Con The State of t	Attorney Docket Number	071949-7001.	:

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
CYL A30		Bonow, R.O., "New insights into the cardiac natriuretic peptides." Circulation 93:1946-1950, (1996).	
	A31	Cagney and Emili, "De novo peptide sequencing and quantitative profiling of complex protein mixtures using mass-coded abundance tagging." <i>Nature Biotechnol</i> . 20: 163-170, (2002).	
	A32	Cannon et al., *Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with Tirofiban: Rationale and study design of the international TACTICS-TIMI 18 trial.* Am. J. Cardiol. 82: 731-6, (1998)	
	A33	Cheng et al., "A Rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study." J. Am. Coll. Cardiol. 37: 386-91, (2001).	
	A34	Cho et al., "Natriuretic peptides and their therapeutic potential." Heart Dis. 1: 305-28, (1999).	<u>                                   </u>
	A35	Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands." <i>Proc. Natl. Acad. Sci. USA</i> 87, 6378-82, (1990).	
	A36	Davidson et al., "C-Type natriuretic peptide." Circulation 93:1155-9, (1996).	
iyl	A37	Devlin et al., "Random peptide libraries: A source of specific protein binding molecules." Science 249, 404-6, (1990).	

	///		-
Examiner Signature	XX.	Date Considered	7/19/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>8</sup>Emter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498(P) Complet if Known INFORMATION DISCLOSURE 10/419,059 Application Numb r. STATEMENT BY APPLICANT 04/17/2003 Filing Date First Named Inventor. Kenneth F. Buechler Group Art Unit Unassigned (use as many sheets as necessary) Examiner Name Unassigned Sheet Attorney Docket Number 071949-7001

			NON PATENT LITERATURE DOCUMENTS	
		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	. Te
LYL A38		A38	Fischer et al., "Evaluation of a new, rapid bedside test for quantitative determination of B-Type natriuretic	
			peptide." Clin. Chem. 47: 591-594, (2001).	Ì.
				ļ.
_		A39	Gobinet-Georges et al. "Stability of brain natriuretic peptide (BNP) in human whole blood and plasma." Clin.	-
			Chem. Lab. Med. 38: 519-23, (2000).	ľ
- 1				2
+		A40	Hamm et al., "Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin	<u> -</u>
		740	T levels." N. Engl. J. Med. 340: 1623-9, (1999).	1
			1 levels. 14. Eligi. J. Med. 340, 1023-3, (1333).	]
				ļ
		A41	Hartree, "Determination of protein: A modification of the lowry method that gives a linear photometric	·
			response." Anal Biochem 48: 422-427, (1972).	
1		•	·	;
7	$\neg$	Ā42	Hunt et al., "The role of the circulation in processing pro-Brain natriuretic peptide (proBNP) to amino-	-
- 1	.	•	terminal BNP and BNP-32." Biochem. Biophys. Res. Comm. 214: 1175-83, (1995).	:   .
1				,
		A43	Hunt et al., 'The amino-terminal portion of pro-Brain natriuretic peptide (Pro-BNP) circulates in human	·  -
- 1			plasma." Peptides 18: 1475-81, (1997).	
				·
				:
	.	A 4 4		<u> </u>
		A44	Huse et al., "Application of a Filamentous phage pVII fusion protein system suitable for efficient production,	
LY	1		screening, and mutagenesis of F(ab) antibody fragments." Journal of Immunology, 140: 3914-3920,	
	.		(1992).	

Examiner Signature	LK	.Date . Considered	7/19/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450. Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

NOV 1 2 2003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1992 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form	1449B	PYOTRADEN	ARK		Compl te if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Numb r	10/419,059	
					Filing Dat	04/17/2003	
					First Nam d Inv ntor	Kenneth F. Buechler	:
					Group Art Unit	Unassigned	
(use as many sheets as necessary)					Examiner Name	Unassigned	
Sheet	4	of	8		Attorney Docket Number	071949-7001	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	er Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue publisher, city and/or country where published.							
114	A45	Issaq et al., "SELDI-TOF MS for diagnostic proteomics." Anal. Chem. 75: 149A-155A, (2003).						
LYL			1.					
- 1								
	,							
	A46	Issaq et al., "The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification."	1.					
		Biochem. Biophys. Res. Commun. 292: 587-92, (2002).						
			1:					
			;					
			1.					
	A47 .	Kalra et al., "Myocardial production of C-Type natriuretic peptide in chronic heart failure." Circulation 107:	1:					
		571-3, (2003).	1.					
			.					
			1:					
	A48	Lowry et al., "Protein measurement with the folin phenol reagent." J. Biol. Chem. 193: 265, (1951).	+					
	A49	Merchant and Weinberger, "Recent advancements in surface-enhanced laser desorption/ionization-time of	1					
		flight-mass spectrometry." Electrophoresis 21: 1164-67, (2000).						
			1:					
	A50	Morrow et al., "Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in	<del> </del>					
		unstable angina: A TIMI-11B substudy." J. Am. Coll. Cardiol. 36: 1812-7, (2000).						
LYL								
			1					

		 	• :
Examiner Signature	LK	Date Considered	7/19/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 2Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P Compl te if Known INFORMATION DISCLOSURE 10/419,059 **Application Number** STATEMENT BY APPLICANT 04/17/2003 Filing Dat First Named Inv ntor Kenneth F. Buechler Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 8 Attorney Docket Number 071949-7001

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s) publisher, city and/or country where published.				
1.4	A51	Motwani et al., "Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme				
CYL		inhibition after myocardial infarction." Lancet 341: 1109-13, (1993).				
.						
<u> </u>	150					
	A52	Murdoch et al. "Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid				
		assay: Implications for clinical practice." Heart 78: 594-7, (1997).				
_	A = 2	Alacard Harrison (China Card and Card a				
1 1	A53	Ng and Ilag, "Biomedical applications of protein chips." J. Cell Mol. Med. 6: 329-340, (2002).				
			:			
<del>-}</del> i	A54	Norman et al. "Degradation of brain natriuretic peptide by neutral endopeptidase: Species specific sites of	+-			
1 1		proteolysis determined by mass spectrometry.* Biochem. Biophys. Res. Commun. 28: 175: 22-30, (1991).				
1			:			
1	A55	Prickett et al., "Identification of amino-terminal Pro-C-Type natriuretic peptide in human plasma." Biochem.	+			
		Biophys. Res. Commun. 286:513-7, (2001).				
LYL						
			:			
		•	1			

	·	· · · · · · · · · · · · · · · · · · ·
Examiner Signature	Date Considered	7/19/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>8</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995,

1101110011				444			
	Substitute f	or form 1449B	Pto	•		Compl te if Known	
	INFORMAT	ION DISCLO	SUREZO	CC!	Application Number	10/419,059	<del></del>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT MARK O					Filing Dat	04/17/2003	
					First Nam d Inventor	Kenneth F. Buechler	
					Group Art Unit	Unassigned	-
(use as many sheets as necessary)					Examiner Name	Unassigned	
Sheet	. 6	of	8		Attorney Docket Number	071949-7001	1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> <sup>6</sup>
1. 14	A56	Ridker et al., "Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in	
LYL		patients with average cholesterol levels." Circulation 98: 839-44 (1998).	ŀ
			1.
•	A57	Scott and Smith, "Searching for peptide ligands with an epitope library." Science 249, 386-88, (1990).	1.
'			1
			:
			:
	A58	Shimizu et al., "Degradation of human brain natriuretic peptide (BNP) by contact activation of blood	1
		coagulation system." Clin. Chem. Acta 305: 181-6, (2001).	
.			
	A59	Shimizu et al., "Molecular forms of human brain natriuretic peptide in plasma." Clin. Chem. Acta 316: 129-	
1		35, (2002).	:
			;
	A60	Smith et al., "Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral	
ŀ	AOU	endopeptidase." J. Endocrinol. 167: 239-46, (2000).	
. \			
1			
	A61	Tateyama et al., "Concentrations and molecular forms of human brain natriuretic peptide in plasma."	1
. '.		Biochem. Biophys. Res. Commun. 185:760-7, (1992).	
141			;
LIL			1:
			.

	///	· · · · · · · · · · · · · · · · · · ·		:	
Examiner Signature	XX		Date Considered	7/19/06	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office; PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

persons are required to respond to a collection of information unless it contains a valid OMB control Under the Paperwork Reduction Act of 1995.

number.				· ·	
	Substitute f	or form 1449E	BIPTO TRADEMA		Complet if Known
	INFORMAT	ION DISCLO	SURE	Application Numb r	10/419,059
	STATEMEN	IT BY APPL	ICANT	Filing Dat	04/17/2003
				First Nam d Inventor	Kenneth F. Buechler
	•			Group Art Unit	Unassigned
	(use as many	sheets as ne	ecessary)	Examiner Name	Unassigned
Sheet	7	of	8	Attorney Docket Number	071949-7001

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	A62	Trindade and Rouleau, "Vasopeptidase inhibitors: potential role in the treatment of heart failure." Heart Fail.					
LYL.		Monit. 2: 2-7, (2001).					
			1.				
-	A63	Troughton et al., "Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-	<del> </del>				
ŀ		BNP) concentrations." Lancet 355: 1126-30, (2000).					
		, , , , , , , , , , , , , , , , , , , ,	Ë				
			;				
ľ							
	A64	Van Veldhuisen et al., "High-Versus low-dose ACE inhibition in chronic heart failure: A double-blind,	+-				
		placebo-controlled study of Imidapril." J. Am. Coll. Cardiol. 32: 1811-8 (1998).					
ļ		process-consisted study of anticaphia. V. Ant. Con. Cardiol. 32, 4611-6 (1990).					
			r				
	A65	Venugopal, "Cardiac natriuretic peptides – hope or hype?" J. Clin. Pharm. Ther. 26: 15-31, (2001).	╀				
· <b> </b>	7.00	verlagopal, Odrolae Hauturelle pepildes - Hope of Hyper 3. Ollif. Filanni, Ther. 20. 10-51, (2001).					
			'				
<del></del>	A66	Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from	╀				
1		Escherichia coli." <i>Nature</i> 341:544-546, (1989).	H				
1	'	Containing con. Mainte of Cott. 240' (1202).					
LYL							
÷							

	•	
Examiner Signature	Date Considered	7/19/06

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

OTP E

HDV 1 2 2003

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, appersons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complet if Known INFORMATION DISCLOSURE **Application Number** 10/419,059 STATEMENT BY APPLICANT Filing Dat 04/17/2003 First Nam d Inv ntor Kenneth F. Buechler Group Art Unit Unassigned (use as many sheets as necessary, Examiner Name Unassigned 8 Sheet Attorney Docket Number 071949-7001

		NON PATENT LITERATURE DOCUMENTS	7
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	∶T⁵
121	A67	Wilson, "Simplified conjugation chemistry for coupling peptides to F(ab') fragments; autologous red cell	
agglutination assay for HIV-1 antibodies." J. Immunol. Methods 175:267-273, (1994).			
			-
	A68	Wright et al., "Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a	1
		novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures."	
		Prostate Cancer and Prostatic Diseases 2: 264-76, (1999).	
_	A69	Varmuch "Coupling of antihody binding fragments to colid phase currents site diseased hinding of E/ohl)	Ļ.
(	AUS	Yarmush, "Coupling of antibody-binding fragments to solid-phase supports: site-directed binding of F(ab') <sub>2</sub>	
LYL	•	fragments." J. Biochem. Biophys. Methods 25:85-97, (1992).	:
٠, ٥			.

Examiner Signature	Date Considered	7/19/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached

• •

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

nomoer.				· · · · · · · · · · · · · · · · · · ·		
	Substitute for	form 1449B	BILER		Complete if Known	
	INFORMATIO	N DISCLØ	SURE \$\	Application Number	10/645,874	······································
	STATEMENT	BY APPLI	CANT , 1 2004 2	Filing Date	08/20/2003	
		-{	HON SI MAN	First Named Inventor	Buechler et al.	***************************************
		/	0	Group Art Unit	1645	
·	(use as many sh	eets as ne	SESSIV) TRABENA	Examiner Name		
Sheet	.1	of	1 TRABE	Attorney Docket Number	071949-7002	

U.S. PATENT DOCUMENTS										
Examiner Cite No.1	0	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,				
		No.1 Number Co	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear				
LYL	A1	5352587		Chang et al.	10-04-1994					
LYL	A2	5422393		Bricker et al.	06-06-1995					
			<del>                                     </del>			<u> </u>				

				F	DREIGN PATENT DOCUMENT	TS		
Examiner Initials*	Cite No. <sup>1</sup>	Fore Office <sup>3</sup>	eign Patent D Number <sup>4</sup>	Ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		•	,					

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A3	International Search Report and the Written Opinion of the International Searching Authority from PCT Application No. PCT/US04/12024.	1:
			:
			:
			·
			i i

Evention V	
Examiner Signature Date Considered 7/11/06	:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.				$\overline{\alpha}$			
	Substitute fo	or form 1449B	/PTQ	~~	a	Complete if Known	
	INFORMATI	ON DISCLO	SUSE V	w	Application Number	10/645,874	
	STATEMEN	T BY APPLI	CANT	721	Eiling Date	08/20/2003	
	Date Submitte	d: January 2	n blans	* O	Errst Named Inventor	Buechler	
					Group Art Unit	1743	
	(use as many s	sheets as ne	cessar	Aguarel?	Examiner Name		
Sheet	1	of	1	(T'NED	Attorney Docket Number	071949-7002	

				U.S. PATENT DOCUMENTS	3	
Examiner Cite No.1	U.S. Patent	Document .		Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document . MM-DD-YYYY	Passages or Relevant Figures Appear
LYL	A1	5786163		Hall	07-28-1998	
LYL	A2	6627457		Pandian et al.	09-30-2003	
LYL	A3	6670138		Gonzalez-Zulueta et al.	12-30-2003	
						<b>,</b>
			-			

					FO	REIGN PATENT DOCUMENT	TS		-
Examiner Initials*	Cite No. <sup>1</sup>	Fore Office <sup>3</sup>	ign Patent C Number <sup>4</sup>	locument Kind Coo (if know		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LYL	A4	Huttunen et al., "Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. The Journal of Biological Chemistry, 275:40096-40105, 2000.	
LYL	A5	Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisma. Resuscitation, 49:193-199, 2001.	i
LYL	A6	Yakoviev et al., Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. The Journal of Neuroscience, 17(19): 7415-724, 1997.	
	Α7	International Search Report for international application No. PCT/US04/20984	:
•	A8	Notice of References Cited, PTO-892, Part of Paper No. 20041202 from U.S. Application No. 10/225,082 filed August 20, 2002.	

Examiner Signature	XX	Date Considered	7/19/06	:

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. "Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Repervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	PSOEMHOR 10	r form 1449B	/PTO	Complete if Known			
	INFORMATION	ON DISCLO	SURE	Application Number	10/645,874		
	STATEMEN'	BY APPLI	ICANT	Filing Date	08/20/003		
				First Named Inventor	Kenneth F. Buechler		
				Group Art Unit	1646		
	(use as many s	heets as ne	cessary)	Examiner Name			
Sheet	1	of	1	Attorney Docket Number	071949-7002		

				U.S. PATENT DOCUMENTS	3	
	U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines,	
Initials*	Number Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
LYL	A1	6756483		Bergmann et al.	06-29-2004	
LYL	A2	6828107		Asada et al.	12-07-2004	
_		<del></del>			· · · · · ·	
		-				

					F(	REIGN PATENT DOCUMEN	TS		:
Examiner Initials*	Cite No. <sup>1</sup>	F Office	oreign Patent  Number	Documen Kind C (if kno	ode	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
									•
					<u> </u>				
					1				1.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
			:
	·		:

Examiner Signature	AL	Date Considered	7/19/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents, <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

P Substitute for	form 1449B/PT(	)	Complete if Known			
INFORMATIO	N DISCLOSU	RE .	Application Number	10/645,874		
/ STATEMENT			Filing Date	8/20/2003		
SEP 0 6 2005 W			First Named Inventor	Kenneth F. Buechler	-	
\a 3L1 \ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\			Group Art Unit	1645		
(use as nothing sh	eets as neces	sary)	Examiner Name	_		
Sheet & TRADEMARY	of 1		Attorney Docket Number	071949-7002		

U.S. PATENT DOCUMENTS										
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant				
Examiner Cite No.		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear				
	-		<del> </del>							

	FOREIGN PATENT DOCUMENTS										
		Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
			· .					<u> </u>			
					<u> </u>			-			
								1			

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	I tem thook magazine tolimal senal symposium catalog etc i date pagetsi volume-issue dilir						
241	A1	Harter et al., Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury. Journal of Neuroimmunology, 121:76-78, 2001.					
		·	:				
		·					

	$\Lambda_{\Lambda}$		
Examiner Signature		Date Considered	7/14/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

nu <u>mber.</u>	·		OF	·		
	Substitute for	form 1449B/	PTØO 4		Complete if Known	
		·		Application Number	10/645,874	
	INFORMATIO	N DISCLO	SURFICE 0 8 2005	நிing Date	8/20/2003	
	STATEMENT	BY APPLI	SURE O 8 2005	्र्यांrst Named Inventor	Kenneth F. Buechler	
			\7	Croup Act Linit	1645	
	(use as many sh	neets as ne	cessar TRADEMA	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	071949-7002	

				U.S. PATENT DOCUMENTS	5		
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,	
Examiner Cite No.1		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
LYL	A1	5,206,140		Marder et al.	04-27-1993		
LYL	A2	6,309,888		Holvoet et al.	10-30-2001		
IYI	A3	6,461,828		Stanton et al.	10-08-2002		

	U.S. PATENT APPLICATION DOCUMENTS											
Examiner	Cite No.1	Cito	U.S. Patent Ap Docume	•	Name of Potentian or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant					
Initials*		Serial Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant o Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear						

FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. <sup>1</sup>	For Office <sup>3</sup>	eign Patent C Number <sup>4</sup>	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6		

	NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ <sup>8</sup>							
LYL	A4	FONAROW et al., "Combining Natriuretic Peptides and Necrosis Markers in Determining Prognosis in Heart Failure," Reviews in Cardiovascular Medicine, 2003, Suppl. 4, Vol. 4								
LYL	A5	RICHARDS et al., "Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction," Heart, 1999, pp. 114-120, Vol. 81	<b>-</b>							
LYC	A6	SAADY et al., *Left appendage: structure function, and role in thromboembolism,* Heart, 1999, pp. 547-555, Vol. 82	<b> </b>							

***		· · · · · · · · · · · · · · · · · · ·
Examiner Signature	Date Considered	7/19/06

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DLMR\_278158.1

¹ Unique citation designation number. ²See attached Kinds of U.S. Petent Documents. ³Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

IAN 1 9 2006 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute (08 form)	14998/	ΡΤΟ	Complete if Known				
				Application Number	10/645,874			
	INFORMATION DI	SCLOS	SURE	Filing Date	8/20/2003			
	STATEMENT BY	APPLIC	CANT	First Named Inventor	Kenneth F. Buechler			
				Group Art Unit	1743			
	(use as many sheets	as nec	cessary)	Examiner Name	Unassigned			
Sheet	1	of	2	Attorney Docket Number	071949-7002			

U.S. PATENT DOCUMENTS										
Examiner Initials*	0.1	U.S. Patent Document		News of Delayan and a Free Lat	Date of Publication of	Pages, Columns, Lines, Where Relevant				
	Cite No.	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear				
			<u> </u>							
		· · · · · · · · · · · · · · · · · · ·								

	U.S. PATENT APPLICATION DOCUMENTS										
	Cite	U.S. Patent Ap Docume	ont		Filing Date of	Pages, Columns, Lines, . Where Relevant					
	No.1	Serial Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear					

			FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent C Office <sup>3</sup> Number <sup>4</sup>	Ocument .Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
LYL	A1	WO 02/083913		Biosite Diagnostics, Inc.	10-24-2002		
				·			<del>                                     </del>

	NON PATENT LITERATURE DOCUMENTS										
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ <sup>6</sup>								
141	A2	CASSIN et al., È realizzabile una strategia operative piu efficace per la gestione in urgenza del paziente con dolore toracico acuto?, Ital Heart J Suppl, Feb. 2000, pp. 186-201, Vol. 1									
LYL	А3	FUTTERMAN et al., Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A, American Journal of Critical Care, March 2002, pp. 168-172, Vol. 11, No. 2									
LYL	A4	HUNT et al., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment, Clinical Endocrinology, 1997, pp. 287-296, Vol. 47	-								

		4
Examiner Signature	Date Considered	7/19/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁰Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	or form 1449B	/PTO			
				Application Number	10/645,874	
	INFORMATI	ON DISCLO	SURE	Filing Date	8/20/2003	
	STATEMEN	T BY APPL	ICANT	First Named Inventor	Kenneth F. Buechler	
				Group Art Unit	1743	
	(use as many	sheets as ne	cessary)	Examiner Name	Unassigned	
Sheet	2	· of	2	Attorney Docket Number	071949-7002	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LYL	A5	SAGNELLA et al., Measurement and significance of circulating natriuretic peptides in cardiovascular disease, Clinical Science, Nov. 1998, pp. 519-529, Vol. 95, No. 5	
141	A6	SONEL et al., Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels with Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department with Chest Pain, Circulation, Sep. 5, 2000, pp. 1107-1113, Vol. 102, No. 10	
			<u>:</u>
		·	
			:
		·	

Examiner Signature	LK .	Date Considered	7/19/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number number.

	Substitutedout	14498/	PTO		:	
	INFORMATION DI	ISCLO	SURE	Application Number	10/645,874	•
STATEMENT BY APPLICANT				Filing Date	08/20/2003	
			•	First Named Inventor	Kenneth F. Buechler	
				Group Art Unit	1743	
(use as many sheets as necessary)				Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	. 071949-7002	

U.S. PATENT DOCUMENTS										
	0.11	U.S. Patent Document		N	Date of Publication of	Pages, Columns, Lines, Where Relevant				
	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear				
LYL	A1	2003/0022235		Dahlen et al.	01-30-2003					
LYL	A2	5,290,678		Jackowski	03-01-1994					
					·	·				
				<u> </u>						

	U.S. PATENT APPLICATION DOCUMENTS										
Examiner	Cite	U.S. Patent Application Document		Name of Potentiae or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant					
Initials*	No.1	Serial Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear					

FOREIGN PATENT DOCUMENTS											
Examiner Initials*	Cite No.1	For Office <sup>3</sup>	eign Patent C Number <sup>4</sup>	Ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ6			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Te

Examiner Signature		Date Considered	7/19/06						

\*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.